Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations.
P2X7 receptors have emerged as potential drug targets for the treatment of medical conditions such as e.g. rheumatoid arthritis and neuropathic pain. To assess the impact of pharmaceuticals on P2X7, we screened a compound library comprising approved or clinically tested drugs and identified several compounds that augment the ATP-triggered P2X7 activity in a stably transfected HEK293 cell line. Of these, clemastine markedly sensitized Ca(2+) entry through P2X7 to lower ATP concentrations. Extracellularly but not intracellularly applied clemastine rapidly and reversibly augmented P2X7-mediated whole-cell currents evoked by non-saturating ATP concentrations. Clemastine also accelerated the ATP-induced pore formation and Yo-Pro-1 uptake, increased the fractional NMDG(+) permeability, and stabilized the open channel conformation of P2X7. Thus, clemastine is an extracellularly binding allosteric modulator of P2X7 that sensitizes P2X7 to lower ATP concentrations and facilitates its pore dilation. The activity of clemastine on native P2X7 receptors, Ca(2+) entry, and whole-cell currents was confirmed in human monocyte-derived macrophages. Similar effects were observed in murine bone marrow-derived macrophages. Consistent with the data on recombinant P2X7, clemastine augmented the ATP-induced cation entry and Yo-Pro-1 uptake. In accordance with the observation that P2X7 controls the cytokine release from LPS-primed macrophages, we found that clemastine augmented the IL-1β release from LPS-primed human macrophages. Collectively, these data point to a sensitization of the recombinantly or natively expressed human P2X7 receptor toward its physiological activator, ATP, possibly leading to a modulation of macrophage-dependent immune responses.
Rudolf Boehm Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany.
Wolfgang
W
Nörenberg
Christoph
C
Hempel
Nicole
N
Urban
Helga
H
Sobottka
Peter
P
Illes
Michael
M
Schaefer
D000255:Adenosine Triphosphate / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000166:cytology / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002462:Cell Membrane / Q000235:genetics / Q000378:metabolism; D002463:Cell Membrane Permeability / Q000187:drug effects / Q000235:genetics; D002974:Clemastine / Q000494:pharmacology*; D057809:HEK293 Cells; D006801:Humans; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000166:cytology / Q000378:metabolism*; D051379:Mice; D058486:Receptors, Purinergic P2X7 / Q000235:genetics / Q000378:metabolism*
D018926:Anti-Allergic Agents; D053583:Interleukin-1beta; D008070:Lipopolysaccharides; D058486:Receptors, Purinergic P2X7; D000255:Adenosine Triphosphate; D002974:Clemastine; D002118:Calcium
Br J Pharmacol. 2007 Feb;150(4):445-54
17211459
Biophys J. 2007 Aug 1;93(3):846-58
17483156
J Biol Chem. 1997 Feb 28;272(9):5482-6
9038151
J Immunol. 2010 Aug 15;185(4):2611-9
20639492
J Med Chem. 2009 May 28;52(10):3123-41
19191585
J Physiol. 1998 Jul 1;510 ( Pt 1):27-35
9625864
Drug Dev Ind Pharm. 2002;28(2):193-202
11926363
Mol Neurobiol. 2009 Jun;39(3):190-208
19283516
J Biol Chem. 2010 Jul 23;285(30):23147-58
20495003
J Membr Biol. 1988 Jul;103(1):55-66
2460627
J Biol Chem. 2003 Sep 26;278(39):37344-51
12869560
J Pharmacol Exp Ther. 2009 Feb;328(2):409-18
19023039
Mol Cell Biochem. 2002 Sep;238(1-2):69-79
12349911
Pflugers Arch. 2006 Aug;452(5):501-12
16708237
Behav Brain Res. 2009 Dec 1;204(1):77-81
19464323
BMC Immunol. 2008 Jul 15;9:35
18627610
FASEB J. 2008 Mar;22(3):861-9
17928361
Allergol Int. 2008 Sep;57(3):257-63
18566547
Neuropharmacology. 2009 Jan;56(1):208-15
18657557
J Physiol. 1999 Sep 1;519 Pt 2:335-46
10457053
J Immunol. 2009 Jul 1;183(1):578-92
19542469
Purinergic Signal. 2009 Jun;5(2):139-49
19255877
J Immunol. 2004 Jul 15;173(2):1202-8
15240711
J Cell Sci. 2008 Oct 1;121(Pt 19):3261-70
18782864
Pflugers Arch. 1997 Nov;434(6):661-8
9305996
Trends Pharmacol Sci. 2006 Apr;27(4):211-7
16530853
Crit Rev Immunol. 2009;29(4):335-45
19673687
Nat Med. 2009 Oct;15(10):1170-8
19767732
Br J Pharmacol. 2009 Aug;157(7):1215-24
19552691
Eur Biophys J. 2009 Mar;38(3):339-46
18414844
Neuropharmacology. 1997 Sep;36(9):1285-94
9364483
Methods Mol Biol. 2005;290:105-16
15361658
J Neurosci. 2010 Oct 20;30(42):14213-24
20962242
Br J Pharmacol. 1997 Aug;121(7):1429-37
9257924
Biophys J. 2004 Mar;86(3):1488-501
14990476
Br J Pharmacol. 2007 Dec;152(8):1283-90
17934511
Br J Pharmacol. 2007 May;151(1):115-27
17351655
Trends Pharmacol Sci. 2007 Sep;28(9):465-72
17692395
Trends Neurosci. 2006 May;29(5):257-62
16564580
J Immunol. 2010 Jun 15;184(12):7040-6
20488797
J Cell Biol. 2002 Oct 28;159(2):291-302
12391024
J Immunol. 1997 Aug 1;159(3):1451-8
9233643
Neuroscience. 2007 Jun 8;146(4):1817-28
17478048
EMBO J. 2006 Nov 1;25(21):5071-82
17036048
Am J Physiol. 1997 Dec;273(6):C1793-800
9435482
Prog Neurobiol. 2006 Apr;78(6):327-46
16697102
Diabetologia. 2009 Aug;52(8):1579-88
19396427
J Physiol. 1982 Oct;331:599-635
6296372
Nat Commun. 2010 Jul 27;1:44
20975702
Am J Physiol Cell Physiol. 2009 Aug;297(2):C430-9
19494237
J Neurochem. 2007 Apr;101(1):17-26
17394459
Am J Physiol Cell Physiol. 2005 Nov;289(5):C1295-302
16093280
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):12063-8
18689682
Mol Pharmacol. 2006 Jun;69(6):1975-83
16510558
Br J Pharmacol. 2007 Oct;152(4):523-37
17700717
Nat Neurosci. 1999 Apr;2(4):315-21
10204537
Nature. 2009 Jul 30;460(7255):592-8
19641588